Objective: To investigate the ability of Magnetic resonance cholangiopancreatography (MRCP) to exclude choledocholithiasis (CDL) in symptomatic patients. Material and methods: Patients suspected of choledocholithiasis who underwent MRCP from 2008 through 2013 in a population based study at the National University Hospital of Iceland were retrospectively analysed, using ERCP and/or intraoperative cholangiography as a gold standard diagnosis for CDL. Results: Overall 920 patients [66% women, mean age 55 years (SD 21)] underwent MRCP. A total of 392 patients had a normal MRCP of which 71 underwent an ERCP investigation demonstrating a CBD stone in 29 patients. A normal MRCP was found to have a 93% negative predictive value (NPV) and 89% probability of having no CBD stone demonstrated as well as no readmission due to gallstone disease within six months following MRCP. During a 6-month follow-up period of the 321 patients who did not undergo an ERCP nine (2.8%) patients were readmitted with right upper quadrant pain and elevated liver tests which later normalised with no CBD stone being demonstrated, three (0.9%) patients were readmitted with presumed gallstone pancreatitis, two (0.6%) patients were readmitted with cholecystitis and two (0.6%) patients were lost to follow-up. Seven patients of those 321 underwent an intraoperative cholangiography (IOC) and all were negative for CBD stones. For the sub-group requiring ERCP following a normal MRCP the NPV was 63%. Conclusion: Our results support the use of MRCP as a tool for exclusion of choledocholithiasis with the potential to reduce the amount of unnecessary ERCP procedures.
Introduction
Choledocholithiasis (CDL) is a common and potentially severe form of gallstone disease. Around 10-25% of patients diagnosed with gallbladder stones have concomitant common bile duct (CBD) stones, also known as choledocholithiasis (CDL). [1, 2] Magnetic resonance cholangiopancreatography (MRCP), first described in 1991, is widely used as a non-invasive imaging modality in the diagnosis of various pancreaticobiliary conditions. [3, 4] Despite the widespread use of MRCP in many institutions, its role in CDL diagnosis has not been fully established in clinical practise. If the results of MRCP were found to be reliable it could reduce the amount of unnecessary ERCP procedures performed, thereby reducing complications associated with the procedure, such as post-ERCP pancreatitis. [5] [6] [7] Thus, the non-invasive nature of MRCP has attracted attention and been compared with more invasive diagnostic approaches, such as endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP). [6, [8] [9] [10] MRCP has in some studies been shown to have a diagnostic accuracy similar to EUS and ERCP [6, 7, [10] [11] [12] and several studies have found MRCP to be a valuable imaging modality when CDL is suspected, with relatively high negative predictive value (NPV). [7] [8] [9] 11] In contrast, other studies found MRCP to be potentially unreliable with low NPV [13, 14] and/or relatively low sensitivity. [5, 14, 15] Furthermore, many studies on the subject have been conducted on a limited number of patients. [5] [6] [7] [8] [9] 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] Thus, the diagnostic accuracy of MRCP in clinical practise is somewhat controversial.
The aim of this study was to establish the diagnostic accuracy of MRCP, in a large group of patients, especially considering the ability to exclude CDL in symptomatic patients. A secondary objective was to construct a plausible multivariate model based on the outcome of MRCP and various clinical and/or biochemical findings, which could be used as an aid along with MRCP in the exclusion of CDL.
Methods

Patient population
A retrospective study was undertaken on patients undergoing MRCP suspected to have CDL from 2008 through 2013 in the National University Hospital of Iceland. A computerised database at the Department of Radiology was used to identify MRCPs performed during the study period. Relevant clinical data were obtained from medical records. Patients with indications other than CDL were excluded. Other exclusion criteria were as follows: malignancy in or pertaining to the liver, pancreas, biliary system and/or duodenum, ambulatory MRCP investigations, former liver transplant, or major surgery performed on the hepatobiliary system such as hepaticojejunostomy, history of gastric bypass or Roux-en-Y anastomosis, chronic pancreatitis, primary sclerosing cholangitis (PSC), acute viral hepatitis, and Caroli syndrome. MRCPs in children were also excluded.
The following clinical data were collected from medical records: age, gender, length of hospital stay, and duration of gallstone related symptoms. Also laboratory parameters: serum bilirubin, white blood cell count, C-reactive protein (CRP), alkaline phosphatase (ALP), c-glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), amylase, and lipase levels were obtained. ERCP was considered a gold standard diagnosis of CDL and the results of an ERCP following MRCP were registered. If ERCP was not performed, intraoperative cholangiography (IOC) was considered a surrogate gold standard. For patients not undergoing ERCP or IOC, a follow-up time of 6 months was arbitrarily defined and patients were considered stone-free at the end of follow-up if they had not been admitted to hospital with gallstone disease during the period. Furthermore, records of previous or subsequent cholecystectomy were obtained and the timeframe from MRCP to a therapeutic ERCP recorded. It should be noted that ERCP is primarily used as a therapeutic intervention at our institution and patients did not undergo ERCP for diagnostic purposes only.
MRCP imaging
Outcomes of MRCP were recorded retrospectively and based on the evaluation of the attending radiologist at the time of the investigation. When according to the reports of the radiologists the CDL diagnosis was somewhat uncertain, an experienced radiologist, among the authors (PH), re-evaluated the MRCP images.
Variables detected and recorded on MRCP imaging included CBD diameter, CBD stones, intra-and extrahepatic bile duct dilatation, dilatation of the pancreatic duct, cholecystitis, pancreatitis, and gallbladder stones. A CBD above 7 mm in diameter was considered dilated, but in patients with a history of previous cholecystectomy a CBD above 10 mm was considered dilated. An abnormal MRCP investigation was defined as a positive result for any of the variables above, except for gallbladder stones and cholecystitis.
Magnetic resonance imaging (MRI) was performed on a 1.5 T Siemens Magnetom Avanto system (Siemens, Erlangen, Germany). A series of T1-and T2-weigted images were taken, with slice thickness 5-8 mm. The MRCP slice thickness alone was 1 mm. The patients fasted for at least 4 h before the MRCP. Neither spasmolytic agents nor oral contrast agents were administered prior to or during the investigation. Patients were imaged with a body phased-array receive coil. Following are the sequences which were used after the localiser: T2 HASTE (half-Fourier acquisition single shot turbo spin echo) coronal free breath, T2 HASTE axial free breath, T2 fat saturated axial free breath, T1 in and out of phase axial breath hold, T2 HASTE fat saturation thick slab breath hold, and T2 coronal free breath.
Statistical analysis
Group analysis was performed using Student's t-test and Fischer's exact test analysing numeric and dichotomous variables, respectively. A logistic regression analysis was undertaken, with a diagnosed stone, either on ERCP or IOC, acting as the response variable. Positive predictive value (PPV) was calculated for those who had a CBD stone on MRCP and subsequently underwent an ERCP. Negative predictive value (NPV), on the other hand, was calculated for those who presented with a normal MRCP, whether they underwent an ERCP or not. In calculating the sensitivity and specificity of MRCP, true positives, false positives, and false negatives were all confirmed by ERCP or IOC whereas all negative MRCPs for CBD stones were considered true negatives whether that was confirmed by ERCP/IOC or not. p < 0.05 was considered statistically significant. No corrections were made for multiple testing. Statistical analysis was performed using R version 3.0.2 and Microsoft Excel 2010. Statistical review of the study was performed by a biomedical statistician.
Results
In total, 1655 patients underwent an MRCP investigation between January 2008 and December 2013. Thereof 735 patients were excluded according to the above-mentioned predetermined criteria ( Figure 1 ). Overall 920 patients who underwent MRCP due to suspected CDL were included in further analysis, mean age 55 years (SD, 21 years), 607 patients (66%) were women. Overall 392 patients had a normal MRCP of which 71 underwent an ERCP investigation demonstrating a CBD stone in 29 patients (Figure 1 ). A total of seven patients underwent an intraoperative cholangiography (IOC) during subsequent cholecystectomy which all negative for CBD stones (Figure 1 ). During a 6-month follow-up period of the 321 patients who did not undergo an ERCP, nine patients were readmitted with right upper quadrant pain and elevated liver tests which later normalised with no CBD stone demonstrated, three patients were readmitted with presumed gallstone pancreatitis without a CBD stone being identified and two patients were readmitted with cholecystitis. However, in none of these 15 patients ERCP was required and all recovered clinically, the two last mentioned patients underwent cholecystectomy. Two patients with residency outside Iceland were lost to follow-up.
The negative predictive value (NPV) of MRCP was found to be 93% and a normal MRCP investigation gave a 89% probability of having no CBD stone as well as no readmission due to gallstone disease in the following 6 months. PPV, sensitivity and specificity of MRCP for CBD stones were found to be 80, 76, and 94%, respectively.
When selecting only patients who had an ERCP within 48 h from the MRCP investigation, the sensitivity improved and the PPV, sensitivity and specificity were found to be 82, 84, and 95%, respectively. If only patients who underwent ERCP within 24 h were included, only a minor improvement on MRCPs' sensitivity and specificity was observed (making the sensitivity 86% and the specificity 96%). Excluding patients who had a suboptimal MRCP investigation due to motion artefacts or other technical issues (n ¼ 44) did only slightly improve the sensitivity of MRCP, from 84% to 85%.
In the analysis of patients with a normal MRCP and a negative ERCP for CBD stones 24 ERCP investigations were normal, five showed biliary sludge or raised suspicion of stone disease and 13 demonstrated other pathology such as post-operative bile leak, bile duct dilatation and/or papillary stenosis (Figure 1 ). For the sub-group of patients (n ¼ 78) who had a normal MRCP undergoing an ERCP (n ¼ 71) investigation or IOC (n ¼ 7), the NPV of MRCP was found to be 63%. Comparing those who had a stone on ERCP (n ¼ 29) versus those who did not, either on ERCP or IOC (n ¼ 49), those with a demonstrable stone had lower CRP values, 34 (55) versus 77 (116) (p ¼ 0.032), a higher proportion of gallbladder stones on MRCP, 18 (100%) versus 20 (65%) patients (p ¼ 0.004), and a shorter time in hospital, 3.9 (2.2) versus 7.4 (11.5) days (p ¼ 0.045). No significant difference was observed in any of the other variables recorded.
Comparison of those who had a stone demonstrated on MRCP (group 1) and those without a stone (group 2) in terms of demographics, symptoms, laboratory values, and additional results of MRCP is shown in Table 1 . Patients who had a stone demonstrated on MRCP had significantly higher ALP, GGT, AST, ALT, and bilirubin levels, but significantly lower CRP and similar lipase values. Patients with a CBD stone on MRCP also had a wider common bile duct and a higher ratio of concomitant gallbladder stones (Table 1) . Patients without a stone on MRCP had a lower proportion of jaundice and a similar proportion of pancreatitis. After exclusion of patients who were later suspected of alcohol induced pancreatitis (n ¼ 13), the difference in the proportion of pancreatitis between the two groups remained unsignificant.
A comparison of patients with a normal MRCP who on subsequent ERCP were found to have CBD stones (n ¼ 29) Figure 1 . Flow chart, exclusion of patients and fate of patients following MRCP. *Other abnormal result of MRCP included one or more of the following: CBD dilatation, intrahepatic bile duct dilatation, pancreatic duct dilatation, pancreatitis. **All six intraoperative cholangiographies (IOC) were negative for CBD stones. ***Other pathology on ERCP included post-operative bile leak, bile duct dilatation and papillary stenosis.
versus those who had a normal MRCP and no stone disease detected (n ¼ 363) revealed that those who had a stone demonstrated also had lower CRP, higher bilirubin and more often had jaundice. Also, those with a stone had a higher proportion of gallbladder stones (Table 2) .
A logistic regression analysis was undertaken on all patients who underwent the gold standard ERCP or IOC to demonstrate possible predictors of CBD stones. Independent predictors were found to be a negative MRCP for CBD stones, a non-dilated CBD and an absent gallbladder stone (Table 3) . Less significant predictors were non-dilated intrahepatic bile ducts, ALP value below 150 IU/L and a bilirubin value below 60 lmol/L. In the multivariate regression analysis, many combinations of independent predictors were found to be significant (Table 4) . Some independent predictors as well as a combination of predictors showed a tendency towards significance but were not included since no corrections were made for multiple testing.
Discussion
The main results of the current study suggest that MRCP is an important diagnostic tool for the exclusion of choledocholithiasis with a high negative predictive value. Very few patients were readmitted due to suspected gallstone disease within six months following a normal MRCP and for none of these ERCP were required. However, NPV declined in those who were suspected of having CDL despite a normal MRCP and underwent ERCP. Independent predictors of the absence of CBD stones apart from MRCP were found to be a nondilated CBD, an absent gallbladder stone, non-dilated intrahepatic bile ducts, bilirubin and ALP. Patients who had a stone demonstrated on MRCP had a wider CBD, a higher ratio of concomitant gallbladder stones and significantly higher ALP, GGT, AST, ALT, and bilirubin but lower CRP and similar lipase levels. An absent gallbladder stone, either independent or along with bilirubin or ALP, in combination with MRCP, showed significant combined predictive value.
In previous studies, MRCP has been shown to have sensitivity for demonstration of CBD stones ranging from 57% to 100%, specificity of 72-100%, positive predictive value (PPV) of 87-100%, and a negative predictive value (NPV) of 50-100% in the diagnosis of choledocholithiasis. [6, 8, 9, 11, 13, 14, [17] [18] [19] [20] [21] A recent meta-analysis of 25 studies on the detection rate of CBD stones demonstrated an estimated sensitivity of 90% and specificity of 95% for MRCP. [22] It must be noted that many studies reporting low sensitivity and/or NPV of MRCP are more than a decade old and might be outdated due to the technological advancements of MRCP in the period following their publication. [4, 23, 24] However, two recent studies have not demonstrated high NPV of a negative MRCP to exclude CDL. [13, 17] In clinical practise, it is of major importance to exclude CBD stones in order to avoid unnecessary ERCPs. [6, 21] Thus, the clinical problem we wanted to address in the current study was the reliability of a normal MRCP investigation for the exclusion of common bile duct stones. Many factors are known to contribute to the diagnostic challenges in suspected CDL. A considerable proportion of CBD stones pass spontaneously and thereafter do not seem to be clinically significant. [25] [26] [27] The sensitivity of MRCP has also been shown to be less for small stones (<5 mm) and for stones lodged in the ampulla of Vater as can occur during biliary pancreatitis. [16, 28, 29] Many studies analysing the overall diagnostic accuracy of MRCP had a very limited number of participants [5] [6] [7] [8] [9] 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] with a range of 30 [5, 8] to 315 patients. [11] Many of these studies had a variety of different types of patients and different and/or unclear definitions of a normal or negative MRCP. In the current study, we investigated a large number of patients with a clear definition of a normal MRCP. Apart from the large number of patients included, another strength of this study was the unique patient population as our institution is the only hospital in the whole country of Iceland performing MRCP investigations and therefore the missing data was minimal and only two patients with residency outside Iceland were lost to follow-up.
The current study did have some limitations. A limitation of this study as well as others of the same type is the somewhat subjective view of what might be considered a CBD stone on MRCP reported by each radiologist. However, this mirrors the situation in clinical practise and Comparison between those who had a subsequent stone on ERCP and those who had no stone identified. gastroenterologists performing ERCP procedures are also subjects of subjective evaluation of cholangiograms. However, all equivocal cases regarding the presence of CBD stones on an MRCP were re-evaluated by an experienced radiologist and also the equivocal cases on ERCP were reviewed retrospectively by a surgeon with experience of ERCPs. Another important shortcoming owed to the fact that CBD stone size was hugely underreported and could therefore not be recorded as a variable in our study. Finally, investigators were not blinded to the results of either MRCP or ERCP which could have had an effect on their respective interpretation.
Negative predictive value and exclusion of choledocholithiasis
The main results of the current study suggest that when CDL is suspected MRCP has great excluding potential with a high NPV, which is in line with many other studies. [6, 7, 9, 11] However, the NPV was found to be less for patients who subsequently underwent ERCP based on evaluation of clinical symptoms and biochemical parameters, a finding in concert with recent observations. [13, 17] It must be noted that in many cases involving a high suspicion of CBD stones and a subsequent normal MRCP, there is the potential for spontaneous passage of CBD stones. On a similar basis, it is conceivable that some individuals with a normal MRCP and a CBD stone shown on a subsequent ERCP may theoretically have had a stone migration to the common bile duct either spontaneously from the gallbladder or during cholecystectomy after the MRCP had been undertaken. This is supported by our observation, that a substantial amount of false negative MRCPs result from extending the time-frame between MRCP and ERCP beyond 48 h (seen as a reduction in sensitivity), possibly allowing for stones to migrate from the gallbladder. Among those with a normal MRCP, who had a CBD stone demonstrated later on also had a significantly higher proportion of gallbladder stones, making stone migration potentially more likely in those individuals. Thus, the true NPV might be underestimated in our study, but it is also possible that all reported false negatives were truly false negative MRCPs and that our estimation of the NPV is correct. In either case, the NPV of MRCP is high.
PPV, sensitivity, and specificity
The sensitivity (76%) and PPV (80%) of MRCP were somewhat lower than demonstrated in other studies while the specificity was high and in keeping with other reported data. [6, 8, 11, 18, 20, 22] To better clarify these results, we attempted to control for the possibility of previously mentioned stone passage through the ampulla of Vater and also for stone migration from the gallbladder to the common bile duct by considering only MRCPs followed by an ERCP within 48 h. This increased the sensitivity of MRCP whereas the PPV remained lower than expected. [6, 8, 11, 18, 20] Our results also suggest that minor motion or susceptibility artefacts do not have a significant effect on the diagnostic accuracy of MRCP with regard to CBD stones since excluding suboptimal MRCPs did not affect the diagnostic accuracy of MRCP markedly. Furthermore, narrowing the interval between a diagnostic MRCP and a therapeutic ERCP further from the aforementioned 48 h did not improve the diagnostic ability of MRCP, since only a slight improvement in diagnostic accuracy was observed in that sub-group of patients compared to the group undergoing ERCP within 48 h.
Group comparison and the logistic model
A certain group of patients of interest were those who had a normal MRCP undergoing an ERCP investigation. Those who subsequently had a stone demonstrated on ERCP or IOC had lower mean CRP and a shorter duration of hospital stay possibly indicating the effect of immediate therapeutic intervention. A significant proportion of patients who had no stones demonstrated were found to have a post-operative bile leak possibly contributing to higher CRP values and longer hospital stay. We found no clinically significant factors that could further differentiate the two groups other than a higher proportion of gallbladder stones, and so the more precise selection of those truly warranting an ERCP after a normal MRCP is lacking.
In the overall comparison of those who had a stone on MRCP versus those who did not, the observed difference in cholestatic parameters such as bilirubin and ALP as well as other liver tests such as AST and ALT was to be expected. Also, jaundice was more common in those diagnosed with a stone on MRCP. No difference was observed in the proportion of pancreatitis between the two groups, which was an interesting finding, and their lipase levels did not differ significantly. These results suggest that a substantial amount of patients undergoing MRCP for suspected CDL have already had CBD stones pass through the ampulla of Vater and support previous findings showing a significant proportion of CBD stones pass after pancreatitis, biliary colic, and cholecystitis but less commonly after jaundice. [26] Logistic regression analysis revealed that findings on MRCP such as the absence of a CBD stone, a non-dilated bile duct or the absence of a gallbladder stone were unsurprisingly the best and most significant independent predictors for the absence of CBD stones. An important finding was a combined value of predictive capacity when adding the presence or absence of a gallbladder stone and either ALP or bilirubin together with MRCP alone, enhancing the excluding capacity of MRCP.
Alkaline phosphatase (ALP) < 150 IU/L and bilirubin <60 lmol/L were found to have independent predictive value for excluding CBD stones, a finding consistent with other reports. [11, 30] However, in studies assessing the predictive value of biochemical markers for CBD stones after logistic regression, the markers showing predictive value commonly vary. [11, [30] [31] [32] This inevitably undermines the results of any study attempting to identify these potential predictive factors.
Future implications
Considering the high NPV of MRCP in our study it is likely that a considerable number of future patients could be spared an unnecessary ERCP, resulting both in a reduction of adverse outcomes and the cost associated with the procedure. Although a cost-benefit analysis was not performed and the potential reduction of unnecessary ERCP procedures is not fully quantified, our results provide a strong clue and allow clinicians, making a decision regarding a possible ERCP, to better rely on a negative MRCP.
Conclusion
Our results, based on a large number of subjects, show that a normal MRCP has a very high negative predictive value and very few patients are readmitted with CDL symptoms, with no CBD stone demonstrated during a 6-month follow-up. This supports the use of MRCP as a tool for exclusion of choledocholithiasis with the potential to reduce the amount of unnecessary ERCP procedures performed.
